2021 Fall Clinical Dermatology Conference – UCB Presented New Data on Bimekizumab

Returning guest, Dr. Jeffrey Stark, MD, Head of US Medical Immunology at UCB discusses new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 (almost clear) and PASI 100 (completely clear) skin clearance levels compared with other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These data were presented at the 2021 Fall Clinical Dermatology Conference and AMCP Nexus 2021. 

Jeffrey Stark, MD, is the Head of Medical Immunology at UCB and is board-certified in both rheumatology and internal medicine. After completing training at Vanderbilt University and Emory University, he spent several years in full-time rheumatology practice in both private and academic clinical settings. In subsequent industry medical affairs roles, Dr. Stark has focused on medical education, advocacy, data generation, and highlighting the unmet needs of patients with immunologic diseases. In addition to his role at UCB, Dr. Stark serves as a board member of the American College of Rheumatology (ACR) Research Foundation and is a member of the Medical Advisory Board of the Georgia Chapter of the Lupus Foundation. Dr. Stark is also a past President of the Georgia Society of Rheumatology.